



---

## trientine tetrahydrochloride (equivalent to 150 mg trientine) film-coated tablets (Cuprior®)

GMP-Orphan United Kingdom Ltd

04 October 2019

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**trientine tetrahydrochloride (Cuprior®)** is accepted for use within NHSScotland.

**Indication under review:** the treatment of Wilson's disease in adults, adolescents and children  $\geq 5$  years intolerant to D-penicillamine therapy.

Trientine tetrahydrochloride is an alternative to another formulation of trientine with a lower budget impact.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including Monday 5 August 2019.*

**Chairman  
Scottish Medicines Consortium**